Table 3.
TUNEL-positive cells (%) | caspase-3 positive cells (%) | PAR content (CF) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Layer | C | Z100 | INF | Z100 + INF | C | Z100 | INF | Z100 + INF | C | Z100 | INF | Z100 + INF |
ONL | 0.3 ± 0.1 | 3.0 ± 1.1a | 0.4 ± 0.2b | 0.2 ± 0.1c | 0.07 ± 0.04 | 0.2 ± 0.1 | 0.01 ± 0.01b | 0.04 ± 0.03c | 7,647 ± 676 | 22,925 ± 5111a | 15,982 ± 2,019 | 24,970 ± 1,807d,e |
INL | 1.1 ± 0.2 | 2.5 ± 0.4a | 0.8 ± 0.3b | 1.1 ± 0.3 | 0.2 ± 0.1 | 2.1 ± 0.3a | 0.4 ± 0.3b | 0.4 ± 0.1c | 7,019 ± 1,163 | 9,348 ± 2,288 | 11,156 ± 1,879 | 21,511 ± 2,251c,d,e |
GCL | 0.7 ± 0.1 | 2.0 ± 0.4a | 0.6 ± 0.3b | 1.0 ± 0.3 | 0.6 ± 0.3 | 1.3 ± 0.2a | 0.3 ± 0.1 | 0.6 ± 0.2c | 9,891 ± 2,011 | 10,019 ± 2,212 | 10,204 ± 1,496 | 17,134 ± 2,274c,e |
Note: Kruskal-Wallis test and Dunn’s Multiple Comparisons were used. Values different from control are shown by a(P <0.05). Superscripts represent statistical differences (P <0.05) between bZ100 and INF; cZ100 and Z100 + INF; dINF and Z100 + INF; eC and Z100 + INF respectively. ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion nuclear layer; PAR, poly(ADP-ribose) polymers; C: control; Z100: 100 μM Zaprinast; INF: 2 μg/mL Infliximab; Z100 + INF: 100 μM Zaprinast with 2 μg/mL Infliximab; CF: corrected fluorescence.